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Familial aggregation of non-diabetic end-stage renal disease
(ESRD) is found in African Americans and variants in the
apolipoprotein L1 gene (APOL1) contribute to this risk. To
detect genetic associations with milder forms of nephropathy
in the high-risk families, analyses were performed using
generalized estimating equations to assess relationships
between kidney disease phenotypes and APOL1 variants in
786 relatives of 470 families. Adjusting for familial
correlations, 23.1, 46.7, and 30.2% of genotyped relatives
possessed two, one, or no APOL1 risk variants, respectively.
Relatives with two compared with one or no risk variants had
statistically indistinguishable median systolic blood pressure,
urine albumin to creatinine ratio, estimated glomerular
filtration rate (GFR; MDRD equation), and serum cystatin C
levels. After adjusting for age, gender, age at ESRD in
families, and African ancestry, significant associations were
detected between APOL1 with overt proteinuria and
estimated GFR (CKD-EPI equation), with a trend toward
significance for quantitative albuminuria. Thus, relatives of
African Americans with non-diabetic ESRD are enriched for
APOL1 risk variants. After adjustment, two APOL1 risk variants
weakly predict mild forms of kidney disease. Second hits
appear necessary for the initiation of APOL1-associated
nephropathy.
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Association between the G1 and G2 coding variants in the
apolipoprotein L1 gene (APOL1) on chromosome 22q ranks
among the most impressive genetic breakthroughs in complex
disease.1,2 Idiopathic focal segmental glomerulosclerosis
(FSGS), hypertension-attributed nephropathy, non-diabetic
end-stage renal disease (ESRD), and HIV-associated collaps-
ing glomerulopathy in African Americans are now recognized
as one disease spectrum.3 Significantly, shorter kidney
allograft survival in African-ancestry deceased donor kidneys
also relates to the presence of two APOL1 risk variants,
independent from donor race.4 Nephropathy risk variants
have been selected for based upon protection from Trypano-
soma brucei rhodesiense, a cause of African sleeping sickness.1
However, not all individuals inheriting two APOL1 risk
variants will develop nephropathy. Additional genetic and/or
environmental ‘second hits’ are likely required to initiate
kidney disease, interacting with APOL1 risk variants to produce
different renal histological phenotypes.5 HIV infection is clearly
a second hit, typically producing collapsing FSGS with
proliferation of podocytes.6 Podocin gene (NPHS2) variants
may also prove to be genetically mediated second hits.7
The mechanism(s) underlying APOL1-associated nephrop-
athy remain under intensive investigation.8,9 Aggressive
blood-pressure control and use of angiotensin-converting
enzyme inhibitors failed to markedly halt progression of
hypertension-attributed nephropathy to ESRD in the African
American Study of Kidney Disease and Hypertension;10 the
kidney disease in the African American Study of Kidney
Disease and Hypertension has subsequently been shown to be
strongly APOL1 associated.11 Without effective treatments
and barring identification of treatable/preventable second
hits, widespread screening efforts in the African American
population are of unproven benefit. APOL1 risk variants were
associated with a higher prevalence of microalbuminuria and
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higher prevalence of a low glomerular filtration rate (GFR) in
African Americans from the population-based Dallas Heart
Study.12 However, proteinuria and estimated GFR did not
differ significantly between those with two vs. less than two
APOL1 nephropathy risk variants. Close relatives of African
Americans with non-diabetic forms of ESRD are at
exceptionally high risk for developing nephropathy, and
disparate etiologies of nephropathy are often seen in these
families.13–20 Relatives are often considered for living kidney
donation, as well.21 This study assessed the association
between APOL1 nephropathy risk variants and risk of mild
nephropathy in the first-degree relatives of African Amer-
icans with non-diabetic ESRD.
RESULTS
As of December 1, 2011, the Natural History of APOL1-
associated Nephropathy Study recruited 826 African American
children and siblings of index cases with non-diabetic ESRD
and 786 have been genotyped for APOL1 and ancestry
informative markers. One individual was recruited in 249
families, two individuals in 137 families (N¼ 274), and three
individuals in 101 families (N¼ 303). The mean (s.d.) median
age at ESRD in the proband from families was 47.1 (13.4) 47.0
years. Adjusting for familial correlations, 23.1, 46.7, and 30.2%
of genotyped relatives possessed two, one, or zero APOL1 risk
variants, respectively. Table 1 contains demographic and
clinical results in all the 786 first-degree relatives of ESRD
patients, based on the number of APOL1 risk variants. No
statistically significant differences in renal or hypertensive
phenotypes were observed in an additive model. Figure 1
displays the distribution of MDRD (Modification of Diet in
Renal Disease) GFR and urine ACR based on genotypes.
APOL1 associations with FSGS and non-diabetic ESRD
best fit autosomal recessive inheritance. Therefore, unad-
justed association analyses with APOL1 nephropathy risk
variants in categorical (Table 2) and continuous evaluation
of renal phenotypes (Table 3) were performed using a
recessive model. No evidence of association was observed in
either of these analyses. Categorical classifications of GFR
and urine ACR were based upon clinically relevant cut points
(Table 2).
APOL1 association analyses were then performed in all
622 relatives without diabetes mellitus (see Supplementary
Table S1 online). A trend toward association was seen with
urine ACR, but not with other phenotypes. Mean (s.d.)
median urine ACR was 45.5 (257.4) 4.5mg/g in those with
less than two APOL risk variants vs. 58.4 (172.8) 6.1 mg/g in
those with two risk variants (P¼ 0.1006). Supplementary
Table S2 online contains the results of unadjusted associa-
tion analyses limited to the 525 relatives not younger
than 5 years before the age at ESRD in the index case from
their family. This analysis was performed as younger
patients destined to develop nephropathy may not yet
display the phenotype. No significant associations were
observed.
A series of multivariate analyses were then computed,
adjusting for age, sex, age difference from age at ESRD in
probands, and African ancestry. The results in all the relatives
are shown in Table 4, results limited to those without diabetes
mellitus are shown in Supplementary Table S3 online, and
results in participants not younger than 5 years below the age
at onset of ESRD in the index case are shown in
Supplementary Table S4 online. In these analyses, significant
association was detected between APOL1 and urine ACR
X300mg/g in the full sample (P¼ 0.032, full-adjustment)
and non-diabetic sample (P¼ 0.032, full-adjustment); with a
trend in the older age sample (P¼ 0.065). Association was
also observed with log urine ACR in the non-diabetic sample
(P-value 0.050, full-adjustment); with a trend in the full
sample (P-value 0.096). Strong and consistent trends toward
association were seen with GFR using both MDRD and CKD-
EPI (Chronic Kidney Disease Epidemiology Collaboration)
equations in the full, non-diabetic, and older samples
(P-values ranged from 0.050 to 0.0837, full-adjustment). By
contrast, no significant evidence of association was observed
for the dichotomous trait of kidney disease (defined as urine
ACRX30mg/g and/or MDRD GFRo60ml/min per 1.73m2)
or with urine ACR X30mg/g.
Finally, suggestive evidence of diabetes by APOL1 inter-
action effects on cystatin C concentrations was detected. The
observed P-values ranged from 0.1321 to 0.1611 for Log
(cystatin C), and from 0.0674 to 0.0895 for the dichotomous
Table 1 | Demographic and clinical characteristics of participants, based on the number of APOL1 nephropathy risk variants
0 APOL1 risk variants 1 APOL1 risk variant 2 APOL1 risk variants
Variable N Mean±s.d. Median IQR N Mean±s.d. Median IQR N Mean±s.d. Median IQR P-value
African ancestry, % 231 0.78±0.11 0.80 0.12 375 0.78±0.11 0.80 0.13 175 0.79±0.09 0.80 0.13 0.7587
Age, years 234 48.2±12.7 49.0 18.0 377 48.0±13.7 49.0 19.0 175 45.6±13.5 48.0 17.0 0.1886
Age relative to proband, years 233 1.5±9.0 1.0 15.0 374 0.8±8.8 1.0 12.0 173 0.1±9.2 1.0 15.0 0.0181
BMI, kg/m2 233 32.3±8.9 30.6 10.3 376 33.6±9.7 32.1 10.9 175 32.0±9.0 30.5 10.9 0.1070
Cystatin C, mg/l 234 0.8±0.3 0.8 0.26 377 0.8±0.4 0.8 0.22 175 0.8±0.3 0.7 0.29 0.4652
Diastolic BP, mmHg 228 88.1±16.3 85.0 20.3 377 87.0±15.1 85.5 17.0 175 86.9±12.8 85.5 17.5 0.9389
GFR, ml/min per 1.73m2 234 95.3±25.1 96.7 31.2 377 96.1±27.0 95.5 31.5 175 94.1±26.5 92.1 35.3 0.6755
Systolic BP, mmHg 228 131.1±26.0 128.8 27.8 377 131.1±23.8 126.0 29.5 175 128.2±20.7 126.0 26.5 0.5164
Urine ACR, mg/g 234 92.5±559.5 5.0 14.5 377 105.4±610.4 5.4 14.0 175 62.7±173.7 6.4 13.8 0.3506
Abbreviations: ACR, albumin:creatinine ratio; BMI, body mass index; BP, blood pressure; IQR, interquartile range; MDRD GFR, Modification of Diet in Renal Disease estimated
glomerular filtration rate.
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outcome of high vs. low cystatin C concentrations using a
cutoff value of 0.96mg/l. The interaction effect observed with
the dichotomous variable reached statistical significance
(P-value¼ 0.0456) in the fully adjusted model after excluding
all participants who were more than 5 years younger than
their proband. Analyses stratified by diabetes status revealed a
trend for a positive association between APOL1 risk and high
cystatin C levels in non-diabetic individuals (odds ratio 1.95;
P-value¼ 0.0565), and no effect in diabetic individuals (odds
ratio 0.51; P-value¼ 0.2927).
DISCUSSION
Marked familial aggregation of non-diabetic ESRD is
reproducibly observed in African Americans13–19 and
430% of those initiating renal replacement therapy have
close relatives already on dialysis.20 Variation in the APOL1
gene likely accounts for much of this phenomenon,
displaying among the most impressive evidence of associa-
tion in complex human disease. The present study revealed
similar mean and median levels of albuminuria, serum
cystatin C concentration, and estimated GFR among relatives
of African Americans with non-diabetic ESRD, regardless of
the presence of two or less than two APOL1 risk variants. A
high proportion of relatives with and without two APOL1
risk variants had subclinical nephropathy. Multivariable
analyses accounting for age, sex, overall African ancestry,
and age difference from age at ESRD in index cases revealed
weak relationships between APOL1 and urine ACR
4300mg/g and with GFR o60ml/min per 1.73m2 with P-
values ranging from 0.03–0.05, but not with lower levels of
albuminuria (urine ACR X30mg/g).
These data are reassuring in that APOL1 associations
between heavy proteinuria and reduced GFR were detectable
in members of the African American families at high risk for
nephropathy. The 23% frequency of subclinical nephropathy
in these relatives closely resembles frequencies reported in
similar families recruited in Alabama.18 Therefore, our
families appear to be representative of such families in the
southeastern US The frequencies of urine ACR X30mg/g
and ACR X300mg/g in these high-risk families greatly
exceeds those in the National Health and Nutrition
Examination Survey III.22 However, despite the high
prevalence of silent kidney disease, our results suggest there
may be a limited value in the genetic screening of high-risk
first-degree relatives of African Americans with non-diabetic
ESRD simply to detect those enriched for milder forms of
nephropathy. In contrast to albuminuria and mildly reduced
GFR, APOL1 risk variants strongly associate with severe
forms of nephropathy and ESRD. The majority of relatives
with two APOL1 nephropathy risk variants had a normal
GFR without elevated urine ACR. By contrast, we previously
demonstrated the potential benefit in screening African
American deceased kidney donors for these risk variants.4 It
remains possible that APOL1-associated renal diseases may
progress more rapidly to overt proteinuria (rendering
microalbuminuria less helpful) and/or APOL1-associated
microalbuminuria might be hard to identify in a population
with more frequent metabolic syndrome–associated micro-
albuminuria. The families in this study are a unique high-
genetic/high-environmental risk population, likely different
from the general population. Longitudinal follow up is
currently underway to determine risk of progressive nephrop-
athy in family members. In addition, eight relatives with ESRD
(o1% of the study population) were excluded, potentially
limiting our ability to detect association with severe kidney
disease.
The frequencies of two and one APOL1 risk variants were
23.1 and 46.7%, respectively, in this high-risk cohort. This
substantially exceeds the 12 and 39% frequencies in the
general African American population.1,12 Current study
participants had a mean (s.d.) age of 47.6 (13.4) years
(median 49.0) and 22.9% (40/175) of those with two APOL1
risk variants had kidney disease defined as an MDRD GFR
o60ml/min per 1.73m2 and/or urine ACR X30mg/dl,
compared with 21.1% (129/611) of those with fewer than two
risk variants (P¼ 0.63). The mean age at onset of ESRD in
African Americans was 59.2 years in the 2009 US Renal Data
System report.23 When limiting our analysis to association
with an MDRD-estimated GFRo60ml/min per 1.73m2, low
GFR was present in 8% of those with two APOL1 risk
variants, compared towith 7% with fewer than two risk
variants (P¼ 0.66). When considering albuminuria, urine
ACRX30mg/g was observed in 20.0% of those with two risk
variants relative to 17.5% with fewer than two risk variants
(P¼ 0.45). We also observed urine ACR X300mg/g in 7.4%
in individuals with two risk variants relative to 4.1% in those
with zero or one copy of the risk variant (P¼ 0.07).
Differences in renal and hypertensive phenotypes were not
seen when contrasting those with zero, one, or two APOL1
risk variants (Table 1). Accounting for familial relationships
and adjusting for participant age, sex, age difference
from ESRD onset in probands, and ancestry revealed
evidence of association with urine ACR 4300mg/g and
GFR by APOL1 genotypes
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Figure 1 |Distribution of glomerular filtration rate (GFR) and
urine albumin:creatinine ratio (ACR) by APOL1 genotypes.
Bars represent minimum and maximum readings. Bars spanning
boxes refer to 75% (top), median (middle), and 25% (lower).
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GFR o60ml/min per 1.73m2, but not with low level albu-
minuria or the dichotomous kidney disease trait defined as
urine ACR X30mg/g and/or low MDRD GFR.
Similar results were reported by Friedman et al.12 in the
large population-based Dallas Heart Study. In the Dallas Heart
Study, non-diabetic African American participants had a mean
(s.d.) age of 44.8 (10.3) years. Microalbuminuria and/or
MDRD GFRo60ml/min per 1.73m2 were observed in 19.2%
of non-diabetic subjects with two APOL1 risk alleles, relative
to 6.7% of those with fewer than two risk variants. However,
mean MDRD GFR and urine ACR values were similar and
within the normal range in participants from both groups. The
major difference between our family-based results and the
Dallas Heart Study is seen in those with fewer than two APOL1
risk variants; far lower frequencies of kidney disease were
detected in Dallas Heart Study samples relative to these high-
risk relatives of index cases with non-diabetic ESRD.
The present results and those of the Dallas Heart Study
strongly support the concept of a second inherited or
environmental ‘hit’ required to initiate fall in GFR or
Table 2 | Unadjusted APOL1 associations in the full sample (categorical variables; recessive model)
0/1 APOL1 risk variants 2 APOL1 risk variants Full sample
Variable, category N % N % N % P-value
Kidney diseasea, no 482 78.1 135 21.9 617 78.5 0.6205
Kidney diseasea, yes 129 76.3 40 23.7 169 21.5
Hypertension, no 346 76.9 104 23.1 450 57.7 0.5976
Hypertension, yes 259 78.5 71 21.5 330 42.3
Sex, male 249 79.6 64 20.4 313 39.8 0.3191
Sex, female 362 76.5 111 23.5 473 60.2
Age o20 years 6 46.2 7 53.8 13 1.7 0.0492
Age 20–30 years 60 74.1 21 25.9 81 10.3
Age 30–40 years 93 80.9 22 19.1 115 14.6
Age 40–50 years 159 76.8 48 23.2 207 26.3
Age 50–60 years 268 78.4 74 21.6 342 43.6
Age X70 years 25 89.3 3 10.7 28 3.6
Proband-participant age difference: from 25 to 15 years 11 64.7 6 35.3 17 2.2 0.4650
Proband-participant age difference: from 15 to 5 years 162 77.1 48 22.9 210 26.9
Proband-participant age difference: from 5 to +5 years 240 80.5 58 19.5 298 38.2
Proband-participant age difference: from +5 to +15 years 172 75.8 55 24.2 277 29.1
Proband-participant age difference: 4 +15 years 22 78.6 6 21.4 28 3.6
MDRD GFR o60ml/min per 1.73m2 43 75.4 14 24.6 57 7.3 0.8250
MDRD GFR 60–90ml/min per 1.73m2 205 76.2 64 23.8 269 34.2
MDRD GFR 90–120ml/min per 1.73m2 274 79.0 73 21.0 347 44.1
MDRD GFR X120ml/min per 1.73m2 89 78.8 24 21.2 113 14.4
Urine ACR 0–30mg/g 504 78.3 140 21.7 644 81.9 0.1911
Urine ACR 30–299mg/g 82 78.8 22 21.2 104 13.2
Urine ACR X300mg/g 25 65.8 13 34.2 38 4.8
Urine ACR o30mg/g 504 78.3 140 21.7 644 81.9 0.4508
Urine ACR X30mg/g 107 75.4 35 24.6 142 18.1
Urine ACR 0–17mg/g (males only) 179 80.3 44 19.7 223 71.3 0.6209
Urine ACR X17mg/g (males only) 70 77.8 20 22.2 90 28.7
Urine ACR 0–25mg/g (females only) 298 76.6 91 23.9 389 82.2 0.9349
Urine ACR X25mg/g (females only) 64 76.2 20 23.8 84 17.8
Cystatin C o0.96mg/l 491 77.9 139 22.1 630 80.2 0.7853
Cystatin C X0.96mg/l 120 76.9 36 23.1 156 19.8
Abbreviations: ACR, albumin:creatinine ratio; MDRD GFR, Modification of Diet in Renal Disease estimated glomerular filtration rate.
aKidney disease defined as an MDRD GFR o60ml/min per 1.73m2 and/or urine ACR 430mg/g.
Table 3 | Unadjusted APOL1 associations in the full sample (continuous variables; recessive model)
0/1 APOL1 risk variants (N=611) 2 APOL1 risk variants (N=175)
Variable Mean s.d. Median Mean s.d. Median P-value
African ancestry, % 0.78 0.11 0.80 0.79 0.09 0.80 0.2974
Age, years 48.1 13.3 49.0 45.6 13.5 48.0 0.0159
Age relative to proband, years 0.1 8.9 0.0 0.1 9.2 1.0 0.7226
BMI, kg/m2 33.1 9.4 31.5 32.0 9.0 30.5 0.1380
Cystatin C, mg/l 0.8 0.3 0.8 0.8 0.3 0.7 0.6054
Diastolic BP, mmHg 87.4 15.6 85.5 86.9 12.8 85.5 0.9140
MDRD GFR, ml/min per 1.73m2 95.8 26.3 95.9 94.1 26.5 92.1 0.4325
Systolic BP, mmHg 131.1 24.6 127.0 128.2 20.7 126.0 0.1525
Urine ACR mg/g 100.5 591.0 5.2 62.7 173.7 6.4 0.2184
Abbreviations: ACR, albumin:creatinine ratio; BMI, body mass index; BP, blood pressure; MDRD GFR, Modification of Diet in Renal Disease estimated glomerular filtration rate.
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development of albuminuria in those with two APOL1 risk
variants. Although approximately 70% of cases of idiopathic
FSGS in African Americans is APOL1 associated, it appears
that the majority of middle-aged African Americans with
either one or two APOL1 risk variants do not have kidney
disease. Nonetheless, a 10-fold increase in risk for FSGS and
ESRD is observed in those with two APOL1 risk variants. HIV
infection is a strongly associated environmental second hit.6
Fifty percent of those with two APOL1 risk variants and
untreated HIV infection will develop HIVAN, in contrast to
the 18% explained fraction (or proportion of total risk) of
idiopathic FSGS cases attributable to APOL1. Accounting for
the recessive APOL1 genetic effect is predicted to reduce the
prevalence of HIV-associated collapsing glomerulopathy and
idiopathic FSGS by 67% in the African American population.6
Based on the results in this high-risk family-based study
and the Dallas Heart Study, we suggest caution before
embarking on widespread APOL1 screening to detect mild
nephropathy in the African American community. At
present, it appears that recording a family history of ESRD
and routinely measuring urine ACR and estimated GFR may
be more effective tools for detecting asymptomatic mild
nephropathy. This recommendation will change upon
identification of novel treatments and/or remediable second
hits that initiate nephropathy. The Natural History of
APOL1-associated Nephropathy Study is now following these
participants longitudinally. Those with two APOL1 risk
variants, with and without nephropathy, will be contrasted to
detect interactive genetic risk variants and evidence of
environmental exposures (e.g., non-HIV viral infections)
that may trigger progressive nephropathy in genetically
susceptible individuals.
There are limitations to this report. By design, many of
our participants were related and eight relatives who had
ESRD were not included owing to the study design (788/796
or 99% of available relatives were recruited). Most have had
only a single visit and they are relatively young. The current
cross-sectional data will give way to longitudinal data, and
follow up has begun. Some unaffected relatives will likely
develop future nephropathy, whereas low-level albuminuria
may regress in others. These phenomena will occur in both
the APOL1 risk and non-risk groups. The Dallas Heart Study
report also utilized cross-sectional data and a follow-up visit
is planned. Familial data were addressed by applying
generalized estimating equations. We expected to see reduced
GFR and/or albuminuria in the majority of subjects with two
APOL1 risk variants destined to develop ESRD by the age of 5
years before the age at ESRD in the index case from their
family. An earlier age at ESRD has been reported in those
with two, relative to one, relative to zero copies of the APOL1
G1 variant (49±14.9 vs. 55.9±16.7 vs. 61.8±17.1 years,
respectively; P¼ 1 10–6).24 The mean age of our partici-
pants approaches the age at ESRD in the G1 homozygous
group from the Kanji et al.24 report. Additional strengths of
our study were adjustment for genome-wide African
ancestry, consideration of the age at ESRD in the index case
from each family, and a relatively large sample size.
Asymptomatic first-degree relatives of ESRD index cases are
a unique resource, more difficult to recruit than prevalent
dialysis patients.
In this era of personalized medicine, geneticists are
understandably rushing to translate genetic association
results in the clinical setting. APOL1 demonstrates among
the highest odds ratio for genetic association with severe
kidney disease and ESRD seen in any complex disease.
Nonetheless, the results of this report in African Americans
multiplex ESRD family members at high risk for nephro-
pathy, as well as in a large population-based study, support
Table 4 |Multivariate APOL1 association analyses in the full sample (recessive model)
Outcome Model Estimate s.e. Lower CI Upper CI Z P-value
MDRD GFR 1 1.6947 2.2773 6.1581 2.7687 0.74 0.4568
2 3.7055 2.0167 7.6581 0.2471 1.84 0.0661
3 3.8112 2.0378 7.8052 0.1827 1.87 0.0614
CKD-EPI GFR 1 1.1306 2.1892 5.4214 3.1601 0.52 0.6055
2 3.5187 1.8506 7.1459 0.1085 1.9 0.0573
3 3.6583 1.8696 7.3226 0.0059 1.96 0.0504
Log urine ACR 1 0.163 0.1431 0.1174 0.4433 1.14 0.2546
2 0.2095 0.1434 0.0715 0.4905 1.46 0.1439
3 0.2391 0.1435 0.0422 0.5204 1.67 0.0957
Kidney disease 1 0.09 0.2132 0.328 0.5079 0.42 0.6731
2 0.1733 0.2232 0.2642 0.6107 0.78 0.4376
3 0.2144 0.2246 0.2258 0.6545 0.95 0.3398
Urine ACR X30mg/g 1 0.143 0.2209 0.29 0.576 0.65 0.5175
2 0.2021 0.2265 0.2418 0.6461 0.89 0.3722
3 0.2422 0.2277 0.2042 0.6886 1.06 0.2875
Urine ACR X300mg/g 1 0.7162 0.3513 0.0277 1.4047 2.04 0.0415
2 0.7191 0.3542 0.0249 1.4132 2.03 0.0423
3 0.7607 0.3551 0.0647 1.4568 2.14 0.0322
Abbreviations: ACR, albumin:creatinine ratio; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD GFR, Modification of Diet in Renal Disease estimated
glomerular filtration rate.
Kidney disease reflects either urine ACR X30mg/g and/or MDRD GFR o60ml/min per 1.73m2.
Estimate = b coefficient; Z= (Estimate/s.e.).
Model 1 = ancestryadjusted; Model 2 =Model 1+age and sex; Model 3 =Model 2+age difference from ESRD in proband.
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that the majority of middle-aged individuals with two APOL1
nephropathy risk variants will not manifest clinical nephro-
pathy. Efforts to detect second hits that facilitate the
development and progression of nephropathy, particularly
treatable environmental risk factors and gene–gene interac-
tions, should aggressively be pursued in order to further our
understanding of the pathogenesis of APOL1-associated
nephropathy.5,7 There appears to be a role for screening
African-ancestry donor kidneys and living donors for APOL1
risk variants in order to gauge likelihood of long-term
allograft survival; however, additional studies on the effect of
APOL1 on allograft outcome and allograft or recipient
selection are necessary.21 APOL1 has a strong effect on a wide
range of non-diabetic forms of severe kidney disease in
African Americans. However, it has only marginal effects on
mild perturbations in renal function and low-level albumi-
nuria. This observation may provide important clues to
mechanisms of action. At present, caution should be
exercised before screening African Americans for APOL1
genotypes to predict risk of mild nephropathy. We note that
21% of the first-degree relatives of high-risk African
American ESRD families possessing zero or one APOL1 risk
variants also had subclinical nephropathy, a finding that
reflects other, as yet unidentified, risk factors.
MATERIALS AND METHODS
Study participants
The ‘Natural History of APOL1-associated Nephropathy Study’
recruited up to three siblings and/or children without ESRD (first-
degree relatives) per family of self-described African Americans with
non-diabetic forms of ESRD, including nephropathy attributed to
hypertension, FSGS, HIV-infection, or unknown cause in non-
diabetic subjects.8 Parents were not recruited, nor were siblings or
children who had ESRD (on dialysis or a functioning kidney
transplant). We excluded eight participants who were diagnosed
with ESRD during the screening visit. Eligible relatives who reported
having diabetes mellitus were included. Siblings and offspring were
eligible if they were no more than 15 years below the age at ESRD in
the proband from their family (relatives older than the age at ESRD
of their proband were included). Relatives were genotyped for
APOL1 nephropathy risk variants and genome-wide ancestry
informative markers, which were used for individual ancestry
proportion estimation. Fasting serum, ethylenediaminetetraacetic
acid plasma, urine, buffy coat, and DNA samples were collected and
phenotyping performed for sub-clinical kidney disease and
associated risk factors (e.g., blood pressure, fasting blood sugar,
and body mass index (BMI)). Participants will be longitudinally
evaluated in an attempt to detect the natural history of, and triggers
for, APOL1-associated nephropathy.
Genotype analysis
DNA extraction from whole blood was performed using the
PureGene system (Gentra Systems, Minneapolis, MN). Two single-
nucleotide polymorphisms in the APOL1 G1 nephropathy risk
variant (rs73885319; rs60910145) and an indel for the G2 risk
variant (rs71785313) were genotyped on the Sequenom (San Diego,
CA). In addition, 106 di-allelic ancestry informative markers were
genotyped to determine population substructure. Samples included
44 Yoruba (YRI), 39 European American controls, and the 786
African American study participants using Illumina Custom
Genotyping Services (San Diego, CA) or the Sequenom Mass Array
(San Diego, CA).
Laboratory evaluation
Serum creatinine concentrations were measured using creatinase
enzymatic spectrophotometry, blood urea nitrogen using the urease
enzymatic assay, cystatin C using an immunoassay, and urine
albumin:creatinine ratio (ACR) by microalbumin immunoturbidi-
metric methods at Laboratory Corporation of America (LabCorp;
Burlington, NC; www.labcorp.com). Urine ACR values X30mg/g
were considered elevated (X300mg/g was considered overt
proteinuria). Estimated GFR was computed using both the four-
variable MDRD25 and CKD-EPI26 equations; MDRD GFR
values o60ml/min per 1.73m2 were considered abnormally low. A
variable reflecting subclinical kidney disease based on urine
ACR X30mg/g and/or MDRD GFR o60ml/min per 1.73m2 was
used, as in Friedman et al.12 Normal values for cystatin C were
o0.95mg/l.
Statistical methods
Genotype frequency estimates were adjusted for familial correlation
using McPeek’s best linear unbiased estimator of allele frequency for
pedigree data.27 This estimate is given by (1TK11)11TK1X where
1 is vector of ones, K is the expected kinship coefficient matrix, and
X is the observed genotype at the G2 six base pair insertion deletion
marker and rs73885319, one of the two G1 single-nucleotide
polymorphisms that are in perfect linkage disequilibrium. This
estimate was multiplied by a factor of 0.5 to account for the fact that
APOL1 genotype is effectively a combination of the genotypes
observed at these two markers.
We used the Wilcoxon two-sample test for comparing the
distribution of all continuous outcomes between individuals who
carry two copies of the APOL1 risk variant and those who have zero
or one copy (recessive coding), and its generalization; the
Kruskal–Wallis test for comparing the observed distributions in
the three genotypes (additive coding). Association with categorical
outcomes was tested using w2 tests with the appropriate degree of
freedom.
A series of generalized estimating equations assuming exchange-
able correlation and using the empirical estimate of the variance to
adjust for familial correlation was computed to test for associations
between renal phenotypes and APOL1 risk genotypes.28 This
approach could lead to type I error inflation for markers with low
minor allele frequency in more complex pedigrees. However, this
approach is expected to perform well in this case, given the observed
allele frequencies and study design including only first-degree
relatives. The Box–Cox method was applied to identify the
appropriate transformation of each outcome variable that would
best approximate the distributional assumptions of conditional
normality and homogeneity of variance of the residuals.29 Age, sex,
age relative to age at ESRD in probands, and ancestry adjustments
were incorporated, after an initial unadjusted analysis. These models
were fitted using GFR, urine ACR, and cystatin C, respectively, as the
outcome variable defined both on the continuous scale, as well as
categorical variables using clinically meaningful cutoff values.
Standard regression diagnostics for colinearity and influence were
computed for each model reported. Finally, we tested for interaction
effects between gender and APOL1 status, and between diabetes
status in relatives and APOL1 on these outcome variables using the
same set of covariates.
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